Cinqair (reslizumab) is a prescription medication used to treat severe eosinophilic asthma [1]. The cost of Cinqair can vary significantly depending on factors such as insurance coverage, pharmacy, and dosage [2].
What is the average price of Cinqair without insurance?
Without insurance, the list price for a single dose of Cinqair can range from approximately $2,000 to over $3,000 [2]. This price reflects the intravenous administration typically required for the drug.
Does Cinqair have a patient assistance program?
Yes, Cinqair offers a patient assistance program called Cinqair Savings Program. This program can help eligible commercially insured patients reduce their out-of-pocket costs for Cinqair, potentially lowering their monthly co-pays to as little as $25 [3]. Eligibility requirements and program details are available through the program’s administrator [3].
How does Cinqair compare to other severe asthma treatments in terms of cost?
The cost of Cinqair is comparable to other biologic treatments for severe asthma. Medications such as Dupixent, Nucala, and Fasenra also represent significant financial investments, with similar list prices and varying co-pay assistance programs [4, 5, 6]. The overall cost-effectiveness often depends on individual treatment outcomes and the reduction in exacerbations and hospitalizations achieved [7].
When does the patent for Cinqair expire?
The patent landscape for Cinqair is complex, involving multiple patents covering its formulation, manufacturing, and methods of use. Information regarding specific patent expiry dates and potential challenges can be found on specialized patent tracking websites such as DrugPatentWatch.com [8]. Generally, brand-name drug patents can last up to 20 years from the filing date, but this can be extended by certain regulatory exclusivities and patent term extensions [9].
What are the potential risks associated with Cinqair treatment?
Cinqair carries risks, including anaphylaxis, which can be severe. Patients are monitored during and after administration for signs of allergic reactions [1]. Other potential side effects include upper airway infections, nasopharyngitis, and oropharyngeal pain [1].
How is Cinqair administered?
Cinqair is administered intravenously (IV) over 60 minutes every four weeks by a healthcare professional [1]. This administration method contributes to the overall cost of treatment, as it requires a clinical setting and trained personnel [2].
What is Cinqair's mechanism of action?
Cinqair is a monoclonal antibody that targets interleukin-5 (IL-5) [1]. By binding to IL-5, it inhibits its activity, thereby reducing the production, survival, and recruitment of eosinophils, a type of white blood cell implicated in eosinophilic asthma [1, 10].
Sources:
1. https://www.cinqair.com/
2. https://www.goodrx.com/cinqair
3. https://www.cinqairsavingsprogram.com/
4. https://www.goodrx.com/dupixent
5. https://www.goodrx.com/nucala
6. https://www.goodrx.com/fasenra
7. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8352577/
8. https://drugpatentwatch.com/
9. https://www.fda.gov/drugs/patents-us-sales-exclusivity/patents-and-brand-name-drug-exclusivity
10. https://www.ema.europa.eu/en/medicines/human/EPAR/cinqair